Keywords
Last Name

Gregory A. Viglianti, PhD

TitleAssociate Professor
InstitutionBoston University School of Medicine
DepartmentMicrobiology
Address72 E. Concord St Housman (R)
Boston MA 02118
Phone(617) 638-7790
ORCID ORCID Icon0000-0002-0244-8293
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Division of Graduate Medical Sciences

 Research Expertise & Professional Interests
Research in my laboratory focuses on two main areas: 1) co-factors that influence the mucosal transmission of HIV-1; and 2) the role of endogenous nucleic acid autoantigens as mediators of systemic lupus erythematosus.

1) Mucosal immune responses of the lower female reproductive tract to sexually transmitted pathogenic microorganisms leads to an inflammatory response that enhances the heterosexual transmission of HIV-1. Inflammation is initiated largely by signaling through members of the Toll-like family of innate immune receptors (TLR) that are activated by pathogen-encoded ligands. This inflammatory response enhances HIV-1 transmission by inducing the recruitment of target immune cells such as Langerhans/dendritic cells (LC/DC), macrophages (MØ)‚ and T lymphocytes to the mucosa and by direct activation of these cells. Recent findings have demonstrated that activation of certain nuclear receptors (NR), including peroxisome proliferator activated receptor (PPAR), liver X receptor (LXR), and glucocorticoid receptor (GR)) potently inhibits TLR-induced inflammatory gene expression in MØ, LC/DC, and epithelial cells. Studies in our laboratory are directed toward evaluating: 1) the ability of ligand-activated NR to inhibit the mucosal transmission of HIV-1, in particular LC/DC-mediated trans-infection of T cells; and 2) the molecular mechanism(s) of how ligand-activated NR inhibit TLR-induced transcription of both HIV-1 and inflammatory cytokine genes.

2) Autoimmune diseases such as systemic lupus erythematosus (SLE) are characterized by the overproduction of antibodies, many of which recognize ribonucleoprotein and/or chromatin related autoantigens. A common feature of these autoantigens is that they include DNA or RNA. Our laboratory, in collaboration with Dr. Ann Marshak-Rothstein, is defining the protein and nucleic acid composition of these immunostimulatory autoantigens and determining whether different forms of apoptosis are capable of selectively releasing these autoantigens from cells, thereby making them accessible to autoreactive B cells.

 NIH RePORTER Grants

Yr Title Project-Sub Proj Pubs
2013 REAGENT / VECTOR CORE 5P01AR050256-11-6677 38
2012 Co-factors in HIV Mucosal Infection 5R01AI073149-05 3
2012 REAGENT / VECTOR CORE 5P01AR050256-10-6677 38
2011 REAGENT / VECTOR CORE 5P01AR050256-09-6677 38
2011 Co-factors in HIV Mucosal Infection 5R01AI073149-04 3
2010 REAGENT / VECTOR CORE 5P01AR050256-08-6677 38
2010 Co-factors in HIV Mucosal Infection 5R01AI073149-03 3
2009 Co-factors in HIV Mucosal Infection 5R01AI073149-02 3
2009 REAGENT / VECTOR CORE 2P01AR050256-06-6677 38
2009 REAGENT / VECTOR CORE 7P01AR050256-07-6677 38
Showing the 10 most recent of 28 results. Show All Results

 Self-Described Keywords
  • Retrovirology: chromatin structure/function: gene regulation: HIV: autoimmunity
  • Retrovirology: nuclear receptors: macrophages: dendritic cells: mucosal transmission: gene regulation: HIV: autoimmunity: Toll like receptors
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Agosto LM, Hirnet JB, Michaels DH, Shaik-Dasthagirisaheb YB, Gibson FC, Viglianti G, Henderson AJ. Porphyromonas gingivalis-mediated signaling through TLR4 mediates persistent HIV infection of primary macrophages. Virology. 2016 Dec; 499:72-81. PMID: 27639573.
    View in: PubMed
  2. Papadopoulos G, Shaik-Dasthagirisaheb YB, Huang N, Viglianti GA, Henderson AJ, Kantarci A, Gibson FC. Immunologic environment influences macrophage response to Porphyromonas gingivalis. Mol Oral Microbiol. 2016 Jun 27. PMID: 27346827.
    View in: PubMed
  3. Moody KL, Uccellini MB, Avalos AM, Marshak-Rothstein A, Viglianti GA. Toll-Like Receptor-Dependent Immune Complex Activation of B Cells and Dendritic Cells. Methods Mol Biol. 2016; 1390:249-72. PMID: 26803634.
    View in: PubMed
  4. Kaczmarek Michaels K, Natarajan M, Euler Z, Alter G, Viglianti G, Henderson AJ. Blimp-1, an intrinsic factor that represses HIV-1 proviral transcription in memory CD4+ T cells. J Immunol. 2015 Apr 1; 194(7):3267-74. PMID: 25710909.
    View in: PubMed
  5. Uccellini MB, Busto P, Debatis M, Marshak-Rothstein A, Viglianti GA. Selective binding of anti-DNA antibodies to native dsDNA fragments of differing sequence. Immunol Lett. 2012 Mar 30; 143(1):85-91. PMID: 22285306.
    View in: PubMed
  6. Hanley TM, Viglianti GA. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J Virol. 2011 Oct; 85(20):10834-50. PMID: 21849441.
    View in: PubMed
  7. Avalos AM, Uccellini MB, Lenert P, Viglianti GA, Marshak-Rothstein A. Fc?RIIB regulation of BCR/TLR-dependent autoreactive B-cell responses. Eur J Immunol. 2010 Oct; 40(10):2692-8. PMID: 20809520.
    View in: PubMed
  8. Hanley TM, Blay Puryear W, Gummuluru S, Viglianti GA. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog. 2010; 6:e1000981. PMID: 20617179.
    View in: PubMed
  9. Yasuda K, Richez C, Uccellini MB, Richards RJ, Bonegio RG, Akira S, Monestier M, Corley RB, Viglianti GA, Marshak-Rothstein A, Rifkin IR. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol. 2009 Sep 1; 183(5):3109-17. PMID: 19648272.
    View in: PubMed
  10. Uccellini MB, Avalos AM, Marshak-Rothstein A, Viglianti GA. Toll-like receptor-dependent immune complex activation of B cells and dendritic cells. Methods Mol Biol. 2009; 517:363-80. PMID: 19378022.
    View in: PubMed
  11. Uccellini MB, Busconi L, Green NM, Busto P, Christensen SR, Shlomchik MJ, Marshak-Rothstein A, Viglianti GA. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol. 2008 Nov 1; 181(9):5875-84. PMID: 18941176.
    View in: PubMed
  12. Busconi L, Lau CM, Tabor AS, Uccellini MB, Ruhe Z, Akira S, Viglianti GA, Rifkin IR, Marshak-Rothstein A. DNA and RNA autoantigens as autoadjuvants. J Endotoxin Res. 2006; 12(6):379-84. PMID: 17254393.
    View in: PubMed
  13. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005 Nov 7; 202(9):1171-7. PMID: 16260486.
    View in: PubMed
  14. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 2005 Apr; 204:27-42. PMID: 15790348.
    View in: PubMed
  15. Kiefer HL, Hanley TM, Marcello JE, Karthik AG, Viglianti GA. Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter. Uncoupling of histone acetylation and chromatin remodeling. J Biol Chem. 2004 Oct 15; 279(42):43604-13. PMID: 15299018.
    View in: PubMed
  16. Marshak-Rothstein A, Busconi L, Rifkin IR, Viglianti GA. The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheum Dis Clin North Am. 2004 Aug; 30(3):559-74, ix. PMID: 15261341.
    View in: PubMed
  17. Hanley TM, Kiefer HL, Schnitzler AC, Marcello JE, Viglianti GA. Retinoid-dependent restriction of human immunodeficiency virus type 1 replication in monocytes/macrophages. J Virol. 2004 Mar; 78(6):2819-30. PMID: 14990701.
    View in: PubMed
  18. Marshak-Rothstein A, Busconi L, Lau CM, Tabor AS, Leadbetter EA, Akira S, Krieg AM, Lipford GB, Viglianti GA, Rifkin IR. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res. 2004; 10(4):247-51. PMID: 15373969.
    View in: PubMed
  19. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003 Dec; 19(6):837-47. PMID: 14670301.
    View in: PubMed
  20. Gallina A, Hanley TM, Mandel R, Trahey M, Broder CC, Viglianti GA, Ryser HJ. Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem. 2002 Dec 27; 277(52):50579-88. PMID: 12218051.
    View in: PubMed
  21. Brown XQ, Hanley TM, Viglianti GA. Interleukin 1 beta and interleukin 6 potentiate retinoic acid-mediated repression of human immunodeficiency virus type 1 replication in macrophages. AIDS Res Hum Retroviruses. 2002 Jun 10; 18(9):649-56. PMID: 12079560.
    View in: PubMed
  22. Center DM, Cruikshank WW, Parada NA, Ryan T, Theodore AC, Viglianti G, Lim KG, Weller PF. Measurement of interleukin 16. Curr Protoc Immunol. 2001 May; Chapter 6:Unit 6.23. PMID: 18432814.
    View in: PubMed
  23. Lodie TA, Reiner M, Coniglio S, Viglianti G, Fenton MJ. Both PU.1 and nuclear factor-kappa B mediate lipopolysaccharide- induced HIV-1 long terminal repeat transcription in macrophages. J Immunol. 1998 Jul 1; 161(1):268-76. PMID: 9647233.
    View in: PubMed
  24. Maciaszek JW, Coniglio SJ, Talmage DA, Viglianti GA. Retinoid-induced repression of human immunodeficiency virus type 1 core promoter activity inhibits virus replication. J Virol. 1998 Jul; 72(7):5862-9. PMID: 9621047.
    View in: PubMed
  25. Viglianti GA, Parada NA, Maciaszek JW, Kornfeld H, Center DM, Cruikshank WW. IL-16 anti-HIV-1 therapy. Nat Med. 1997 Sep; 3(9):938. PMID: 9288705.
    View in: PubMed
  26. Cruikshank WW, Doctrow SR, Falvo MS, Huffman K, Maciaszek J, Viglianti G, Raina J, Kornfeld H, Malfroy B. A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1; 14(3):193-203. PMID: 9117450.
    View in: PubMed
  27. Reinhart TA, Rogan MJ, Viglianti GA, Rausch DM, Eiden LE, Haase AT. A new approach to investigating the relationship between productive infection and cytopathicity in vivo. Nat Med. 1997 Feb; 3(2):218-21. PMID: 9018242.
    View in: PubMed
  28. Maciaszek JW, Parada NA, Cruikshank WW, Center DM, Kornfeld H, Viglianti GA. IL-16 represses HIV-1 promoter activity. J Immunol. 1997 Jan 1; 158(1):5-8. PMID: 8977168.
    View in: PubMed
  29. Maciaszek JW, Talmage DA, Viglianti GA. Synergistic activation of simian immunodeficiency virus and human immunodeficiency virus type 1 transcription by retinoic acid and phorbol ester through an NF-kappa B-independent mechanism. J Virol. 1994 Oct; 68(10):6598-604. PMID: 8083995.
    View in: PubMed
  30. Brojatsch J, Kristal BS, Viglianti GA, Khiroya R, Hoover EA, Mullins JI. Feline leukemia virus subgroup C phenotype evolves through distinct alterations near the N terminus of the envelope surface glycoprotein. Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8457-61. PMID: 1326757.
    View in: PubMed
  31. Viglianti GA, Rubinstein EP, Graves KL. Role of TAR RNA splicing in translational regulation of simian immunodeficiency virus from rhesus macaques. J Virol. 1992 Aug; 66(8):4824-33. PMID: 1629957.
    View in: PubMed
  32. Contag CH, Dewhurst S, Viglianti GA, Mullins JI. SIV from Old World Monkeys. In: Gallo, R.C. and Jay, G., eds. The Human Retroviruses. Academic Press. Orlando, FL. 1991; 245-276.
  33. Viglianti GA, Sharma PL, Mullins JI. Simian immunodeficiency virus displays complex patterns of RNA splicing. J Virol. 1990 Sep; 64(9):4207-16. PMID: 2384918.
    View in: PubMed
  34. Hoover EA, Quackenbush SL, Poss ML, Dornsife RE, Overbaugh JM, Donahue PR, Riedel NO, Vigilanti GA, Khiroya R, Mullins JI. Pathogenic mechanisms of immunodeficiency syndrome and aplastic anemia induced by feline leukemia viruses. Dev Biol Stand. 1990; 72:163-6. PMID: 2178112.
    View in: PubMed
  35. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 1989 Nov 15; 49(22):6318-23. PMID: 2553253.
    View in: PubMed
  36. Dorsett D, Viglianti GA, Rutledge BJ, Meselson M. Alteration of hsp82 gene expression by the gypsy transposon and suppressor genes in Drosophila melanogaster. Genes Dev. 1989 Apr; 3(4):454-68. PMID: 2542128.
    View in: PubMed
  37. Viglianti GA, Mullins JI. Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1. J Virol. 1988 Dec; 62(12):4523-32. PMID: 2846868.
    View in: PubMed
  38. Kornfeld H, Riedel N, Viglianti GA, Hirsch V, Mullins JI. Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature. 1987 Apr 9-15; 326(6113):610-3. PMID: 3104797.
    View in: PubMed
  39. Viglianti GA, Blumenfeld M. Satellite DNA-correlated nucleosomal proteins in Drosophila virilis. Biochem Genet. 1986 Feb; 24(1-2):79-92. PMID: 3008708.
    View in: PubMed
  40. Majumdar SK, Maharam LG, Viglianti GA. Mutagenicity of dieldrin in the Salmonella-microsome test. J Hered. 1977 May-Jun; 68(3):184-5. PMID: 330620.
    View in: PubMed
Gregory's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department